Analyst Upgrade Signal: ESPR from Underweight to Neutral by JP Morgan
Price Target: $6
Report Date: 05-05-2022
Symbol: ESPR - Esperion Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Upgrade Signal: ESPR from Underweight to Neutral by JP Morgan
Price Target: $6
Esperion Therapeutics, Inc. (ESPR)
3891 Ranchero Dr Ste 150
Ann Arbor, MICHIGAN 48108
Phone: 17348873903
Website: http://www.esperion.com
CEO: Mr. Timothy Mayleben
NASDAQ, Nasdaq Global Market
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
best stock trading signals, best stock trading signals, options trade signals, free stock signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228